Description
A PRMT4 inhibitor (IC50 = 6 nM); decreases asymmetric methylation of PABP1 (IC50 = 0.038 µM) and increases levels of demethylated SmB (EC50 = 0.018 µM) in RPMI-8226 multiple myeloma cells; inhibits proliferation in a panel of 36 hematopoietic cancer cell lines (IC50s = <100 µM for 9 out of 15 multiple myeloma cell lines); reduces tumor growth and decreases asymmetric PABP1 methylation in tumor tissue in an RPMI-8226 mouse xenograft model at 75, 150, and 300 mg/kg twice per day; reduces acute mechanical allodynia and thermal hyperalgesia in a mouse model of CCI-induced neuropathic pain at 10 µg
Formal name: 2-[2-[2-chloro-5-[(2R)-2-hydroxy-3-(methylamino)propoxy]phenyl]-6-(3,5-dimethyl-4-isoxazolyl)-5-methyl-4-pyrimidinyl]-2,7-diazaspiro[3.5]nonane-7-carboxylic acid, methyl ester
Synonyms: GSK3359088
Molecular weight: 585.1
CAS: 1628830-21-6
Purity: ≥98%
Formulation: A solid